Pharmacologic Reperfusion Therapy with Indigenous Tenecteplase in 15,222 patients with ST Elevation Myocardial Infarction – The Indian Registry

Iyengar, S. S.; Nair, Tiny; Hiremath, Jagdish; Jadhav, Uday; Katyal, V K; Kumbla, Dayanand; Sathyamurthy, I; Jain, Rajendra K.; Srinivasan, Manivannan

doi:10.1016/j.ihj.2013.06.010

Cited by 12 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An outcome of death was higher in women, and this can be attributed to a higher proportion of diabetics and hypertensives in this subgroup. This scenario has also been observed in other studies when identifying that although the STEAMI incidence was lower in women, mortality is approximately twice as high (Iyengar et al 2013). It is also observed that the TIMI risk score for STEAMI is higher in women (Bagai et al 2014).…”

Section: Discussionsupporting

confidence: 84%

Clinical outcomes of fibrinolytic therapy for prehospital treatment of acute myocardial infarction

et al. 2021

View full text Add to dashboard Cite

Fibrinolytic Therapy (FT) is an important form of treatment for cases of Acute Myocardial Infarction (AMI), especially in those places where Primary Percutaneous Coronary Intervention (PPCI) is not available, which is the main form of treatment and can be used even in the prehospital care. Aimed to describe the clinical outcomes of the use of FT in prehospital care for treating patients with AMI. This research covered a total of 53 patients and was carried out from march to october 2017, referring to the care provided from january 2015 to december 2016 in two stages, in which the first occurred with the Mobile Emergency Service (SAMU) and Walk-in Emergency Care Units (UPA), and the second in the referenced hospital services as gateways to those units. Data were collected from secondary sources. The clinical outcomes of FT considered in the form of absolute and relative frequencies and measures of central tendency were considered. The main signs and symptoms at admission were chest pain (84.62%), sweating (36.54%), dyspnea (26.92%), hypertension (19.23%), nausea (17.31%), malaise (17.31%) and emesis (13.46%). The main characteristic of chest discomfort was chest pain (70.45%). The FT drug administered in all patients was tenecteplase. The median time from symptom-to-door was 180 minutes, while symptom-reperfusion was 300 minutes and door-to-needle 160 minutes. Regarding the outcome, 74.47% had clinical improvement, 19.15% died, 4.25% had refractory AMI and 2.13% had reinfarction. The main characteristic of clinical improvement was the reversal of chest pain (68.57%), characterized as myocardial reperfusion criteria. The present study presented the main outcomes of FT use with improvement of those patients who were treated with it, and shorter times related to chest discomfort and the administration of FT were responsible for increasing the outcomes of clinical improvement and decreasing the outcome of death.

show abstract

Section: Discussionsupporting

confidence: 84%

Clinical outcomes of fibrinolytic therapy for prehospital treatment of acute myocardial infarction

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Iyengar et al analysed the efficacy and safety of tenecteplase in 15,222 patients with STEMI. 4 Overall, 95.43% of patients had clinically successful thrombolysis with higher success rate (96.54%) in patients treated within 3 hours, success rate of 85.38% in those presented in 6 hours. STREAM trial demonstrated that patients presented within 3 hours of symptoms onset and fibrinolysed had better outcome 5 (Shock, CHF or reinfarction upto 30 days).…”

Section: Discussionmentioning

confidence: 85%

“…Similar results were also observed in Indian registry, where more than 90% of CST was seen with tenecteplase including high risk subgroup. 4 In earlier studies, the incidence of diabetes in acute myocardial infarction is 10% -25%. In our study the prevalence was much higher, 49%.…”

Section: Discussionmentioning

confidence: 98%

Study of Tenecteplase in Patients With St Elevated Acute Myocardial Infarction

Sreenivasulu¹,

S²

2018

jemds

View full text Add to dashboard Cite

BACKGROUND The incidence of CAD is increasing rapidly. Thrombolytic therapy revolutionised the treatment of acute STEMI. The efficacy, safety of Tenecteplase in STEMI is very much proved. The objective of this study is to study the efficacy and safety of tenecteplase in patients with ST elevated acute myocardial infarction. MATERIALS AND METHODS This is a retrospective observational study done in 100 patients from June 2016 to May 2017. RESULTS The overall rate of clinically successful thrombolysis (CST) by tenecteplase is 92%. The success rate of delayed administration (> 6 hours) was 84%. 92% had chest pain relief with a medium time of 15 minutes. ST segment resolution was observed in 94% patients. Reinfarction was observed in 3% of patients. Bleeding excluding ICH was observed in 2% of patients. 3 patients died before discharge. No hypotension was observed with tenecteplase. CONCLUSION Our study further reinforced the efficacy and safety of tenecteplase in patients presenting with STEMI including high risk subgroups. Our study confirms the importance of early thrombolysis in Indian Scenario.

show abstract

“…Частота внутричерепных кровоиз-лияний -0,62%, серьёзных кровотечений -3,18%. Задержка с применением препарата более 6 часов от начала ангинозного приступа приводила к увели-чивающейся частоте развития сердечной недостаточ-ности, желудочковых тахиаритмий и в целом -более высокой смертности [16].…”

Section: активаторы плазминогена в неотложной терапии тромбозаunclassified

Plasminogen activators in acute management of thrombosis

Таратухин¹

2013

Russ J Cardiol

View full text Add to dashboard Cite

The paper focuses on the problem of intravascular thrombosis and the methods of its treatment. The data on haemostasis pathophysiology, which underlie the occurrence of acute ischemic events in humans, are presented, together with the data on the action mechanisms of fibrinolytic medications. The focus is on tenecteplase, as a modified agent which is more effective than the native tissue plasminogen activator or its closest derivatives. Russ J Cardiol 2013, 3 (101): 81-84

show abstract

Pharmacologic Reperfusion Therapy with Indigenous Tenecteplase in 15,222 patients with ST Elevation Myocardial Infarction – The Indian Registry

Abstract: This study confirms the safety and efficacy of indigenous tenecteplase in Indian patients with STEMI, including high risk subgroups. It also highlights the fact that delayed treatment denotes denial of benefits of pharmacologic reperfusion therapy.

Cited by 12 publications

References 9 publications

Clinical outcomes of fibrinolytic therapy for prehospital treatment of acute myocardial infarction

Clinical outcomes of fibrinolytic therapy for prehospital treatment of acute myocardial infarction

Study of Tenecteplase in Patients With St Elevated Acute Myocardial Infarction

Plasminogen activators in acute management of thrombosis

Contact Info

Product

Resources

About